

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 001-41705

Azitra, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

46-4478536

(IRS Employer
Identification No.)

**21 Business Park Drive
Branford, CT 06405**

(Address of principal executive offices and zip code)

(203)-646-6446

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock: Par value \$0.0001	AZTR	NYSE American, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Non-accelerated filer

Accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of the registrant's common stock outstanding as of November 14, 2023 was 12,097,643.

AZITRA, INC.
TABLE OF CONTENTS

	<u>Page</u>
<u>PART I - FINANCIAL INFORMATION</u>	F-1
Item 1. <u>Financial Statements</u>	F-1
<u>Condensed Consolidated Balance Sheets</u>	F-1
<u>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</u>	F-2
<u>Unaudited Condensed Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit)</u>	F-3
<u>Unaudited Condensed Consolidated Statements of Cash Flows</u>	F-4
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	F-5
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	1
Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u>	10
Item 4. <u>Controls and Procedures</u>	10
<u>PART II - OTHER INFORMATION</u>	11
Item 1A. <u>Risk Factors</u>	11
Item 6. <u>Exhibits</u>	11

PART I FINANCIAL INFORMATION

ITEM 1. Financial Statements.

AZITRA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2023 (Unaudited)	December 31, 2022
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 4,400,327	\$ 3,492,656
Accounts receivable	—	182,820
Tax credits receivable	40,525	69,666
Income tax receivable	13,722	13,722
Deferred offering costs	—	216,886
Prepaid expenses	409,170	160,133
Total current assets	4,863,744	4,135,883
Property and equipment, net	736,423	846,958
Other assets		
Other assets	47,546	47,507
Financing lease right-of-use asset	43,872	—
Operating lease right-of-use asset	899,619	1,116,697
Intangible assets, net	162,240	219,567
Deferred patent costs	736,800	800,831
Total other assets	\$ 1,890,077	\$ 2,184,602
Total assets	\$ 7,490,244	\$ 7,167,443
LIABILITIES, PREFERRED STOCK, AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	417,928	784,687
Current financing lease liability	14,254	—
Current operating lease liability	301,423	287,384
Accrued expenses	720,095	993,961
Contract liabilities	—	156,000
Total current liabilities	1,453,700	2,222,032
Long-term financing lease liability	29,952	—
Long-term operating lease liability	613,572	840,896
Warrant liability	60,933	70,283
Convertible notes payable, net	—	6,600,000
Total liabilities	2,158,157	9,733,211
Commitments and contingencies (Note 13)		
Preferred stock:		
Series A convertible preferred stock; \$0.0001 par value; 205,385 shares authorized at September 30, 2023 and December 31, 2022; 0 and 205,385 shares issued and outstanding at September 30, 2023 and December 31, 2022 respectively; liquidation value of \$0 and \$3,337,506 at September 30, 2023 and December 31, 2022 respectively	—	3,272,944
Series A-1 convertible preferred stock; \$0.0001 par value; 380,657 shares authorized at September 30, 2023 and December 31, 2022; 0 and 380,657 shares issued and outstanding at September 30, 2023 and December 31, 2022 respectively; liquidation value of \$0 and \$14,274,638 as of September 30, 2023 and December 31, 2022, respectively	—	14,100,533
Series B convertible preferred stock; \$0.0001 par value; 851,108 shares authorized at September 30, 2023 and December 31, 2022; 0 and 391,303 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively; liquidation value of \$0 and \$17,000,159 as of September 30, 2023 December 31, 2022 respectively	—	16,321,065
Stockholders' equity (deficit)		
Common stock; \$0.0001 par value, 100,000,000 shares authorized at September 30, 2023 and December 31, 2022, 12,097,643 and 1,043,988 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	1,210	104
Additional paid-in capital	51,475,425	1,054,138
Accumulated deficit	(46,144,548)	(37,314,552)
Total stockholders' equity (deficit)	5,332,087	(36,260,310)
Total liabilities, preferred stock, and stockholders' equity (deficit)	\$ 7,490,244	\$ 7,167,443

The accompanying notes are an integral part of these condensed consolidated financial statements.

AZITRA, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months September 30, 2023	For the Three Months September 30, 2022	For the Nine Months September 30, 2023	For the Nine Months September 30, 2022
Service revenue - related party	\$ 310,700	\$ 48,500	\$ 596,000	\$ 253,500
Total revenue	310,700	48,500	596,000	253,500
Operating expenses:				
General and administrative	1,755,908	1,054,570	3,443,559	2,583,818
Research and development	548,524	1,364,380	2,188,795	4,425,195
Total operating expenses	<u>2,304,432</u>	<u>2,418,950</u>	<u>5,632,354</u>	<u>7,009,013</u>
Loss from operations	(1,993,732)	(2,370,450)	(5,036,354)	(6,755,513)
Other income (expense):				
Interest income	634	3,201	1,184	4,056
Interest expense	(710)	(31,333)	(166,729)	(66,781)
Employee retention credit	—	—	—	229,813
Forgiveness of accounts payable	—	—	56,285	—
Change in fair value of convertible note	—	—	(3,630,100)	—
Other income (expense)	50,519	(19,038)	(54,282)	(45,365)
Total other income (expense)	<u>50,443</u>	<u>(47,170)</u>	<u>(3,793,642)</u>	<u>121,723</u>
Net loss	(1,943,289)	(2,417,620)	(8,829,996)	(6,633,790)
Dividends on preferred stock	—	(692,246)	(1,355,347)	(2,076,737)
Net loss attributable to common shareholders	<u>\$ (1,943,289)</u>	<u>\$ (3,109,866)</u>	<u>\$ (10,185,343)</u>	<u>\$ (8,710,527)</u>
Net loss per share, basic and diluted	(0.16)	(2.95)	(1.97)	(8.25)
Weighted average common stock outstanding, basic and diluted	12,097,643	1,055,455	5,181,107	1,055,380

The accompanying notes are an integral part of these condensed consolidated financial statements.

AZITRA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED)

	Series A Convertible Preferred Stock		Series A-1 Convertible Preferred Stock		Series B Convertible Preferred Stock		Common Stock		Additional Paid-in-Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount			
Balance - December 31, 2021	205,385	\$ 3,272,944	380,657	\$ 14,100,533	391,303	\$ 16,321,065	1,043,100	\$ 104	\$ 868,163	\$ (26,634,186)	\$ (25,765,919)
Stock-based compensation	—	—	—	—	—	—	—	—	56,983	—	56,983
Exercise of stock options	—	—	—	—	—	—	888	—	1,510	—	1,510
Net loss	—	—	—	—	—	—	—	—	—	(2,326,017)	(2,326,017)
Balance, March 31, 2022	205,385	3,272,944	380,657	14,100,533	391,303	16,321,065	1,043,988	104	926,656	(28,960,203)	(28,033,443)
Stock-based compensation	—	—	—	—	—	—	—	—	53,826	—	53,826
Net loss	—	—	—	—	—	—	—	—	—	(1,890,153)	(1,890,153)
Balance, June 30, 2022	205,385	3,272,944	380,657	14,100,533	391,303	16,321,065	1,043,988	104	980,482	(30,850,356)	(29,869,770)
Stock-based compensation	—	—	—	—	—	—	—	—	44,329	—	44,329
Net loss	—	—	—	—	—	—	—	—	—	(2,417,620)	(2,417,620)
Balance - September 30, 2022	205,385	\$ 3,272,944	380,657	\$ 14,100,533	391,303	\$ 16,321,065	1,043,988	\$ 104	\$ 1,024,811	\$ (33,267,976)	\$ (32,243,061)
	Series A Convertible Preferred Stock		Series A-1 Convertible Preferred Stock		Series B Convertible Preferred Stock		Common Stock		Additional Paid-in-Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount			
Balance - December 31, 2022	205,385	\$ 3,272,944	380,657	\$ 14,100,533	391,303	\$ 16,321,065	1,043,988	\$ 104	\$ 1,054,138	\$ (37,314,552)	\$ (36,260,310)
Issuance of Series B Convertible Preferred Stock	—	—	—	—	23,432	1,124,759	—	—	—	—	1,124,759
Stock-based compensation	—	—	—	—	—	—	—	—	38,794	—	38,794
Net loss	—	—	—	—	—	—	—	—	—	(2,457,179)	(2,457,179)
Balance, March 31, 2023	205,385	3,272,944	380,657	14,100,533	414,735	17,445,824	1,043,988	104	1,092,932	(39,771,731)	(38,678,695)
Conversion of convertible notes payable	—	—	—	—	—	—	1,846,020	185	9,494,887	—	9,495,072
Conversion of preferred stock	(205,385)	(3,272,944)	(380,657)	(14,100,533)	(414,735)	(17,445,824)	7,707,635	771	34,818,530	—	34,819,301
Initial public offering, net of issuance costs of \$1,508,791	—	—	—	—	—	—	1,500,000	150	5,991,209	—	5,991,359
Stock-based compensation	—	—	—	—	—	—	—	—	38,794	—	38,794
Net loss	—	—	—	—	—	—	—	—	—	(4,429,528)	(4,429,528)
Balance, June 30, 2023	—	—	—	—	—	—	12,097,643	1,210	51,436,352	(44,201,259)	7,236,303
Stock based compensation expense	—	—	—	—	—	—	—	—	39,073	—	39,073
Net loss	—	—	—	—	—	—	—	—	—	(1,943,289)	(1,943,289)
Balance - September 30, 2023	—	\$ —	—	\$ —	—	\$ —	12,097,643	\$ 1,210	\$ 51,475,425	\$ (46,144,548)	\$ 5,332,087

The accompanying notes are an integral part of these condensed consolidated financial statements.

AZITRA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the Nine Months Ended September 30,	
	2023	2022
Cash flows from operating activities:		
Net loss	\$ (8,829,996)	\$ (6,633,790)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	97,390	93,515
Amortization of debt discount	—	5,895
Amortization of right-of-use assets	219,658	212,470
Accrued interest on convertible notes	165,939	60,877
Stock based compensation	116,661	155,138
Change in fair value of warrant liability	(9,350)	(420)
Change in fair value of convertible notes	3,630,100	—
Forgiveness of accounts payable	(56,285)	—
Loss on disposal of property and equipment	41,417	7,923
Impairment of intangible assets and patent costs	351,360	—
Changes in operating assets and liabilities:		
Accounts receivable	182,820	75,172
Prepaid expenses	(249,037)	45,636
Other assets	(39)	(39,847)
Tax credits receivable	29,141	48,871
Accounts payable and accrued expenses	(143,662)	(1,864)
Financing lease liability	44,206	—
Operating lease liability	(213,285)	(202,853)
Contract liabilities	(156,000)	(3,500)
Net cash used in operating activities	<u>(4,778,962)</u>	<u>(6,176,777)</u>
Cash flows from investing activities:		
Purchases of property and equipment	(22,882)	(23,198)
Proceeds from sale of property and equipment	—	4,250
Capitalization of deferred patent costs	(208,723)	(117,244)
Capitalization of licenses	(13,096)	(57,372)
Capitalization of patent and trademark costs	(13,573)	(46,406)
Net cash used in investing activities	<u>(258,274)</u>	<u>(239,970)</u>
Cash flows from financing activities:		
Proceeds from convertible notes, net of issuance costs	—	4,350,000
Payment of deferred offering costs	—	(40,703)
Principal payments on finance leases	(46,452)	—
Proceeds from initial public offering, net	5,991,359	—
Proceeds from exercise of stock options	—	1,510
Net cash provided by financing activities	<u>5,944,907</u>	<u>4,310,807</u>
Net change in cash and cash equivalents	907,671	(2,105,940)
Cash and cash equivalents at beginning of period	3,492,656	8,044,262
Cash and cash equivalents at end of period	<u>\$ 4,400,327</u>	<u>\$ 5,938,322</u>
Supplemental disclosure of non-cash investing and financing information:		
Obtaining a right-of-use asset in exchange for lease liability	\$ —	\$ 1,418,502
Obtaining a right-of-use asset in exchange for financing lease liability	\$ 46,452	\$ —
Conversion of note to common stock	\$ 9,495,152	\$ —
Conversion of note to Series B Convertible Preferred Stock	\$ 1,124,759	\$ —

The accompanying notes are an integral part of these condensed consolidated financial statements.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Nature of Operations

Azitra, Inc. was founded on January 2, 2014. It is a synthetic biology company focused on screening and genetically engineering microbes of the skin. The mission is to discover and develop novel therapeutics to create a new paradigm for treating skin disease. The Company's discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides and small molecules for precision treatment of dermatology diseases. On May 17, 2023, the Company changed its name to from "Azitra Inc" to "Azitra, Inc."

The Company maintains a location in Montreal, Canada for certain research activities. This location and operations completed there remained consistent throughout 2022 and into 2023. The Company also opened a manufacturing and laboratory space in Groton, Connecticut during 2021.

Forward Stock Split, Change in Par Value, and Initial Public Offering

In June 2023, the Company completed its initial public offering (IPO) in which it issued and sold 1,500,000 shares of its common stock at a price to the public of \$5.00 per share. The shares began trading on the NYSE American on June 16, 2023 under the symbol "AZTR". The net proceeds received by the Company from the offering were \$6.0 million, after deducting underwriting discounts, commissions and other offering expenses.

Immediately prior to the effectiveness of the Company's registration statement, the Company effected a 7.1-for-1 forward stock split of its issued and outstanding shares of common stock (the Forward Stock Split). On May 17, 2023, the Company changed the par value of its capital stock from \$0.01 to \$0.0001. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the effect of the Forward Stock Split. Refer to Note 8 for additional details relating to the Forward Stock Split.

Going Concern Matters

The unaudited condensed financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, management has identified the following conditions and events that created an uncertainty about the ability of the Company to continue as a going concern. As of and for the nine months ended September 30, 2023, the Company has an accumulated deficit of \$46.1 million, a loss from operations of \$5.0 million and used \$4.8 million to fund operations. These factors among others raise substantial doubt about the Company's ability to continue as a going concern.

Management plans to continue to raise funds through equity and debt financing to fund operating and working capital needs; however, the Company will require a significant amount of additional funds to complete the development of its product and to fund additional losses which the Company expects to incur over the next few years. The Company is still in its clinical phase and therefore does not yet have product revenue. There can be no assurance that the Company will be successful in securing additional financing, if needed, to meet its operating needs.

These conditions and events create an uncertainty about the ability of the Company to continue as a going concern for twelve months from the date that the financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Reclassification

Certain prior period amounts and disclosures have been reclassified to conform to the current period's financial presentation.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2. Summary of Significant Accounting Policies

Basis of Accounting

The financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”).

Unaudited Interim Financial Information

The unaudited interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information, within the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis consistent with the audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented and of the financial condition as of the date of the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial statements related to the three and nine months are unaudited. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2022, and notes thereto that are included in the Company’s Registration Statement filed with the SEC on June 5, 2023.

Use of Estimates

The preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet. While management believes the estimates and assumptions used in the preparation of the financial statement are appropriate, actual results could differ from those estimates.

Cash and Cash Equivalents

For purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid investments with original maturities of three months or less to be cash equivalents.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range from 3 to 10 years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations in the period of disposal.

Accounts Receivable

The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based on a history of past write-offs, collections and current conditions. There was no allowance for doubtful accounts at September 30, 2023 and December 31, 2022. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

Deferred Offering Costs

The Company capitalized deferred offering costs, which primarily consisted of direct, incremental legal, professional, accounting, and other third-party fees relating to the Company’s initial public offering. In June 2023, the Company consummated its IPO and recorded such amounts against the gross proceeds of its IPO within the statements of stockholders’ equity during the nine months ended September 30, 2023

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (“Topic 842”). ASU 2016-02 requires lessees to present right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases with terms longer than 12 months. See Note 2 – Recently Adopted Accounting Pronouncements.

In calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance, the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months. Leases are classified as either operating or financing leases based on the economic substance of the agreement.

The Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling \$1,418,502 as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company’s option to extend certain leases ranges from 36 – 52 months. All options to extend have been included in the calculation of the ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions.

At September 30, 2023, the Company had operating right-of-use assets with a net value of \$899,619 and current and long-term operating lease liabilities of \$301,423 and \$613,572, respectively.

In 2023, the Company entered into a lease for the use of certain equipment that is classified as a finance lease. The finance lease has a term of 36 months. At September 30, 2023, the Company had financing right-of-use assets with a net value of \$43,872 and current and long-term operating lease liabilities of \$14,254 and \$29,952, respectively.

Intangible Assets

Intangible assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite life.

The Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, *Goodwill and Other Intangible Assets* (ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have finite lives will continue to be amortized over their useful lives. Impairment losses relating to license agreements were \$78,606 during each of the three and nine months ended September 30, 2023 and \$0 during each of the three and nine months ended September 30, 2022.

Deferred Patent Costs

Deferred patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval. These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent is not issued, the costs associated with the patent will be expensed in the year the patent was rejected. Impairment losses relating to deferred patent costs were \$272,754 during each of the three and nine months ended September 30, 2023 and \$0 in the three and nine months ended September 30, 2022.

Impairment of Long-Lived Assets

In accordance with ASC Topic 360-10, *Accounting for the Impairment or Disposal of Long-Lived Assets* (ASC 360-10), the Company’s policy is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these assets. The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual disposition of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the present value of the net future operating cash flows generated by the asset.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Convertible Debt and Warrant Accounting

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in ASC 480, *Distinguishing Liabilities from Equity* ("ASC 480") and ASC 815, *Derivatives and Hedging* ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income/loss.

Convertible debt

When the Company issues debt with a conversion feature, it first assesses whether the debt should be accounted for in accordance with ASC 480 – Distinguishing Liabilities from Equity. If the debt does not meet the criteria of an ASC 480 liability, the note's conversion features require bifurcation in accordance with ASC 815 – Derivatives and Hedging. If the Company determines the embedded conversion feature requires bifurcation in accordance with ASC 815, the Company also considers if it can elect the fair value option. If the fair value option is elected, the Company records the note at its initial fair value with any subsequent changes in fair value recorded in earnings. As noted in Note 7, the Company has elected the fair value option for the 2022 Convertible Notes and will record the notes at their initial fair values with any subsequent changes in fair value recorded in earnings. The Convertible Notes were converted into the Company's common stock on the Closing Date of the Company's IPO.

Convertible Preferred Stock

As the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock, the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet.

As noted in Note 8, at the Closing Date of the Company's IPO, the Convertible Preferred stock converted into shares of the Company's common stock.

Revenue

The Company follows the *five* steps to recognize revenue from contracts with customers under ASC 606, Revenue from Contracts with Customers ("ASC 606"), which are:

- Step 1: Identify the contract(s) with a customer
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognize revenue when (or as) a performance obligation is satisfied

The Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related to the research and development aspects of the agreement over time using the input method as work is performed on the contract.

The Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research institutions for general research conducted by the Company to further their product development and are therefore considered contributions to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under Topic 606, as the U.S. Government would not meet the definition of a customer.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Amounts earned under these grant contracts are recorded as a reduction to research and development expense when eligible expenses are incurred and the right to payment is realizable or realized and earned. The Company believes this policy is consistent with Topic 606, to ensure that recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606. Additionally, the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under Topic 606.

Receipts of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the contract, are classified as contract liabilities in the accompanying balance sheets.

Research and Development

The Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, *Research and Development*. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist of costs related to labor, materials and supplies. Research and development costs incurred were \$548,524 and \$2,188,795 during the three and nine months ended September 30, 2023, respectively. Research and development costs incurred were \$1,364,380 and \$4,425,195 during the three and nine months ended September 30, 2022, respectively.

At September 30, 2023 and December 31, 2022, the Company has a state tax credit receivable of \$32,459 for pending refunds related to the selling of research and development tax credits back to the State of Connecticut. At September 30, 2023 and December 31, 2022, the Company has \$0 and \$28,925, respectively for pending refunds related to Canadian Scientific Research and Experimental Development (SRED) credits. At September 30, 2023 and December 31, 2022, the Company has also recorded \$8,066 and \$8,282, respectively, related to refunds of Canadian Goods and Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in other income on the statements of operations.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, *Compensation-Stock Compensation* (ASC 718). ASC 718 requires employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements. Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the performance condition will be achieved. The Company recognized the effect of forfeitures when the forfeitures occur.

The Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the expected risk-free interest rate. These assumptions reflect the Company's best estimates, but they involve inherent uncertainties based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based compensation cost could be materially impacted in future periods.

The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting Standards Update (ASU) No. 2018-07, *Improvements to Nonemployee Share-Based Payment Accounting*, which expands the scope of ASC 718 to include share-based payment transactions to non-employees.

The following assumptions are used in valuing options issued using the Black-Scholes option pricing model:

Expected Volatility. The expected volatility of the Company's shares is estimated based on the average volatility of peer companies.

Expected Term. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual term for each grant, or for each vesting-tranche for awards with graded vesting.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Underlying Common Stock Value. The underlying common stock value of the Company's shares is estimated by a third-party valuation expert up until the Company's IPO, at which time the Company utilized its trading price on the NYSE American on the date of grant.

Risk-free Interest Rate. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal to the expected term of the underlying grant.

Dividend Yield. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend yield percentage of zero.

Income Taxes

The Company uses the liability method of accounting for income taxes, as set forth in ASC 740, Accounting for Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates.

Management has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant financial statement exposure to uncertain income tax positions at September 30, 2023 and December 31, 2022. The Company's income tax returns have not been examined by tax authorities through December 31, 2022.

Fair Value Measurements

The Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used to prioritize the inputs to fair value valuation techniques:

- Level 1 – Inputs are based upon observable or quoted prices for identical instruments traded in active markets.
- Level 2 – Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3 – Inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

Financial Instruments

The Company's financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short-term maturities of such instruments. The estimated fair value of the Company's long-term debt approximates carrying value.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). This ASU requires a lessee to recognize a right-of-use asset and a lease liability under most operating leases in its balance sheet. The ASU is effective for annual and interim periods beginning after December 15, 2021. The Company adopted ASU 2016-02 on January 1, 2022. See Note 13 – Operating Leases.

In December 2019, the FASB issued ASU No. 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes*. This standard simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing additional reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted this standard effective January 1, 2022, which did not have a material impact to the financial statements.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In August 2020, the FASB issued ASU No. 2020-06, *Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)*, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This standard will be effective for the Company on January 1, 2024, with early adoption permitted (but no earlier than fiscal years beginning after December 15, 2020). The Company has adopted this standard effective January 1, 2021, which did not have a material impact to the financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.

3. Employee Retention Credit

The CARES Act provides an employee retention credit (“CARES Employee Retention credit”), which is a refundable tax credit against certain employment taxes of up to \$5,000 per employee for eligible employers. The tax credit is equal to 50% of qualified wages paid to employees during a quarter, capped at \$10,000 of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through September 30, 2021. Based on these additional provisions, the tax credit is now equal to 70% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to \$10,000 of qualified wages per quarter. In April 2022, the Company determined it qualified for the tax credit under the CARES Act and recorded a receivable for \$229,813 and recognized the amounts as other income on the statement of operations. The Company received full payment for the amount in September 2022.

4. Property and Equipment

Property and equipment consisted of the following at September 30, 2023 and December 31, 2022:

	<u>September 30, 2023</u>	<u>December 31, 2022</u>
Laboratory equipment	\$ 1,008,063	\$ 1,034,579
Computers and office equipment	30,825	30,825
Furniture and fixtures	24,316	24,316
Leasehold improvements	28,855	28,855
Building equipment	14,932	14,932
Total property and equipment	1,106,991	1,133,507
Less accumulated depreciation & amortization	(370,568)	(286,549)
Total property, plant, and equipment, net	<u>\$ 736,423</u>	<u>\$ 846,958</u>

Depreciation expense was \$30,571 and \$92,000 for the three and nine months ended September 30, 2023, respectively. Depreciation expense was \$30,208 and \$90,165 for the three and nine months ended September 30, 2022, respectively.

For the three and nine months ended September 30, 2023 there was \$41,417 of loss on disposal of property and equipment recorded, respectively. For the three and nine months ended September 30, 2022 there was \$7,923 of loss on disposal of property and equipment recorded, respectively.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

5. Intangible Assets

Intangible assets consisted of the following at:

September 30, 2023:

	<u>Estimated Useful Life</u>	<u>Gross Amount</u>	<u>Accumulated Amortization</u>	<u>Impairment</u>	<u>Net Amount</u>
Trademarks	Indefinite	\$ 56,409	\$ —	\$ —	\$ 56,409
Patents	17 years	119,361	13,530	—	105,831
License agreement	17 years	78,606	—	78,606	—
Intangible assets		<u>\$ 254,376</u>	<u>\$ 13,530</u>	<u>\$ 78,606</u>	<u>\$ 162,240</u>

December 31, 2022:

	<u>Estimated Useful Life</u>	<u>Gross Amount</u>	<u>Accumulated Amortization</u>	<u>Impairment</u>	<u>Net Amount</u>
Trademarks	Indefinite	\$ 53,999	\$ —	\$ —	\$ 53,999
Patents	17 years	108,198	8,140	—	100,058
License agreement	17 years	65,510	—	—	65,510
Intangible assets		<u>\$ 227,707</u>	<u>\$ 8,140</u>	<u>\$ —</u>	<u>\$ 219,567</u>

During the three and nine months ended September 30, 2023, amortization expense related to intangible assets was \$2,013 and \$5,390, respectively. During the three and nine months ended September 30, 2022, amortization expense related to intangible assets was \$1,890 and \$3,350, respectively. During the three months ended September 30, 2023, the Company expensed the remainder of the licensing costs as the patent is not yet granted.

6. Accrued Expenses

Accrued expenses consisted of the following at:

	<u>September 30, 2023</u>	<u>December 31, 2022</u>
Accrued expenses:		
Employee payroll and bonuses	\$ 272,950	\$ 371,010
Vacation	57,963	27,082
Research and development projects	130,233	316,389
Interest	—	223,792
Professional fees	255,794	24,502
Other	3,155	31,186
Total accrued expenses	<u>\$ 720,095</u>	<u>\$ 993,961</u>

The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on research and non-clinical trial milestones. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of expense. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual or prepaid expense accordingly. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.

7. Convertible Debt

In September 2022, the Company entered into a Convertible Note Purchase Agreement (the Agreement) to issue up to \$4,500,000 convertible promissory notes. On the same day, the Company entered into convertible promissory notes (2022 Convertible Notes) with three investors totaling \$4,350,000. The 2022 Convertible Notes mature on January 13, 2023 or the occurrence of an Event of Default (as defined) and bear interest at a rate of 8% per annum which shall accrue but is not due and payable until conversion or full repayment of outstanding principal. The principal and interest outstanding under the 2022 Convertible Notes is automatically converted a) upon the closing of a Qualified Financing resulting in gross proceeds to the Company of at least \$20 million into securities issued in connection with the Qualified Financing, at a discount of 30% per share; b) upon the closing of a Change of Control event into shares of capital stock of the Company or Series B preferred stock; and c) upon the closing of a Public Company Event, into shares of capital stock being issued to investors equal to two-times (2x) the amount of the outstanding principal and accrued interest then outstanding divided by the public offering price per share. The principal and interest outstanding under the 2022 Convertible Notes is convertible, at the option of the holders, at the maturity date into a new class of Company's Preferred Stock (Series C Preferred) equal to the quotient of the outstanding principal amount plus interest divided by the Capped Price, which is defined as the price per share equal to the Valuation Cap of \$30 million divided by the Company Capitalization, as defined in the Agreement.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In February 2023, the 2022 Convertible Notes were amended to extend the maturity date to March 31, 2023 and to change the conversion price upon a Qualified Financing or Change in Control event to \$30 million divided by the number of shares of the Company's common stock issued and outstanding, on a fully diluted basis, immediately prior to the close of the Qualified Financing or Change in Control event.

During April and June 2023, the 2022 Convertible Notes were further amended to extend the maturity date to September 30, 2023 and allow for the sale of additional notes of \$500,000 for a total aggregate principal of \$4,850,000.

Effective June 21, 2023, the 2022 Convertible Notes were converted to 1,846,020 shares of the Company's common stock equal to \$9,494,887. Upon conversion, the Company recorded a change in fair value of \$0 and \$3,630,100 for the three and nine months ended September 30, 2023, respectively, which was recognized as a non-cash change in fair value in Other Income (Expense) on the statement of operations.

The Company accounts for the 2022 Convertible Notes under ASC 815. Under 815-15-25, the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825. The Company has made such election for the 2022 Convertible Notes. Using the fair value option, the convertible promissory note is to be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. The Company evaluates the change based on the conversion price at the current market value. When recognized, changes in the estimated fair value of the notes are recognized as a non-cash gain or loss in Other Income (Expense) on the statements of operations.

Effective January 5, 2021, the Company entered into a Note Purchase Agreement to issue up to \$2,000,000 of convertible promissory notes. On the same date, the Company entered into a convertible promissory note (2021 Convertible Note) with one investor for \$1,000,000. The 2021 Convertible Note bears interest at a rate of 6% per annum and is due and payable in full on January 5, 2023. The 2021 Convertible Note automatically converts upon a qualified equity financing, as defined in the note agreement to the number of shares equal to all principal and accrued interest divided by the conversion price of \$48.00, which is subject to adjustment as defined in the note agreement. The 2021 Convertible Note is also optionally convertible as defined in the note agreement for certain non-qualified financing, a change in control, or upon the maturity date of the 2021 Convertible Note. The Company incurred issuance costs of \$15,613 related to the 2021 Convertible Note, which has been recorded as a debt discount and will be amortized over the term of the 2021 Convertible Note.

In January 2023, the Company elected to convert the 2021 Convertible Note, including interest accrued but not yet paid of \$124,759 at a conversion price of \$48.00 into 23,432 shares of its Series B Preferred Stock in accordance with the terms outlined in the Note Purchase Agreement.

The Company evaluated the terms and conditions of the Note Purchase Agreement related to the 2021 Convertible Note in order to assess the accounting considerations under ASC 480 – Distinguishing Liabilities from Equity, and ASC 815 – Derivatives and Hedging. The Company determined the Convertible Note does not meet any of the criteria to be accounted pursuant to an ASC 480 liability. The Company also assessed the embedded features pursuant to the guidance in ASC 815 and determined the embedded features do not meet any of the criteria for bifurcation.

Convertible notes payable consisted of the following at:

	<u>September 30, 2023</u>	<u>December 31, 2022</u>
2021 Convertible Note	\$ —	\$ 1,000,000
2022 Convertible Notes	—	5,600,000
Total convertible notes	\$ —	\$ 6,600,000

There was \$0 amortized related to the debt issuance costs during the three and nine months ended September 30, 2023, respectively. There was \$1,968 and \$5,904 amortized related to the debt issuance costs during the three and nine months ended September 30, 2022, respectively. Interest accrued on the convertible notes was \$0 and \$223,792 at September 30, 2023 and December 31, 2022, respectively.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

8. Stockholders' Equity

On May 17, 2023, the Company effected a 7.1-for-1 forward stock split (the "Forward Stock Split") of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company's preferred stock. The par value of the common stock was adjusted as a result of the Forward Stock Split from \$0.01 to \$0.0001 and the authorized shares were increased to 100,000,000 shares of common stock in connection with the Forward Stock Split. Fractional shares resulting from the Forward Stock Split were rounded down to the next whole share and in lieu of any fractional shares the Company will pay a cash amount to the holder of such fractional share. The accompanying financial statements and notes to the financial statements give retroactive effect to the Forward Stock Split for all periods presented. Shares of common stock underlying outstanding stock-based awards and other equity instruments were proportionately increased and the respective per share value and exercise prices, if applicable, were proportionately decreased in accordance with the terms of the agreements governing such securities.

Common Stock

At September 30, 2023 and December 31, 2022, per the Company's amended and restated Certificate of Incorporation, the Company was authorized to issue 100,000,000 shares of \$0.0001 par value common stock.

The Company had 12,097,643 and 1,043,988 shares of common stock issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders and the holders of the Common Stock are entitled to elect one director of the Corporation.

The Company currently has 1,611,991 shares of common stock reserved for future issuance for the potential exercise of stock options and warrants outstanding at September 30, 2023.

Preferred Stock

At September 30, 2023 and December 31, 2022, per the Company's amended and restated Certificate of Incorporation, the Company has authorized 1,437,150 shares of \$0.0001 par value preferred stock.

In January 2023, the Company issued 23,432 shares of its Series B Preferred Stock related to conversion of the 2021 Convertible Note at a conversion price of \$48.00 per share (see Note 7).

The Series A, Series A-1, and Series B Preferred Stock have the following rights, preferences and privileges:

Conversion

The preferred stock is convertible, at the option of the holder, into common shares based upon a predefined formula. A holder of preferred stock may convert such shares into common shares at any time. For purpose of conversion, the initial conversion price is \$16.25 per share (original issue price) for Series A Preferred Stock, \$37.50 per share (original issue price) for Series A-1 Preferred Stock, and \$43.45 per share (original issue price) for Series B Preferred Stock, and is subject to adjustment as described in the Certificate of Incorporation. Preferred stock will automatically convert into common shares upon the earlier of (a) an initial public offering with gross proceeds in excess of \$100,000,000 or (b) the date and time, or the occurrence of an event, specified by vote or written consent of the required preferred stock shareholders, all outstanding Series A, Series A-1, and Series B Preferred Stock shall automatically convert into common shares, at the then effective conversion rate.

Upon the Company's IPO in June 2023, all of the outstanding preferred stock converted to common stock, resulting in the issuance of 1,458,233, 2,964,849, and 3,284,553 shares of common stock in exchange for outstanding Series A, Series A-1, and Series B Preferred Stock, respectively. There was no gain or loss upon conversion.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Voting Rights

The holders of the Series A, Series A-1, and Series B Preferred Stock are entitled to vote on any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of preferred stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. The holders of the Series A and Series A-1 Preferred Stock are each entitled to elect one director of the Corporation. The holders of the Series B Stock are entitled to elect two members of the Board. Each class of preferred stock can remove from office such directors and to fill any vacancy caused by the resignation, death or removal of such directors under certain circumstances as described in the Certificate of Incorporation.

Dividends

The holders of Series A Preferred Stock are entitled to receive dividends at a rate of 8% per annum of the Series A original issue price of \$16.25 per share on each outstanding share of Series A Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock). Dividends accumulate from the original date of issuance of the Series A Preferred Stock, are cumulative and are payable upon declaration of the Board of Directors or liquidation of the Company. At September 30, 2023, there were no cumulative dividends on Series A Preferred Stock as there was no longer any Series A Preferred Stock outstanding.

The holders of Series A-1 Stock are entitled to receive dividends at a rate of 8% per annum of the Series A-1 original issue price of \$37.50 per share on each outstanding share of Series A-1 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A-1 Preferred Stock). Dividends are cumulative and are payable upon declaration of the Board of Directors or liquidation of the Company. At September 30, 2023, there were no cumulative dividends on Series A-1 Preferred Stock as there was no longer any Series A-1 Preferred Stock outstanding.

The holders of Series B Stock are entitled to receive dividends at a rate of 8% per annum of the Series B original issue price of \$43.45 per share on each outstanding share of Series B (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock). Dividends are cumulative and are payable upon declaration of the Board of Directors or liquidation of the Company. At September 30, 2023, there were no cumulative dividends on Series B Preferred Stock as there was no longer any Series B Preferred Stock outstanding.

Liquidation

In the event of any liquidation, dissolution or winding up of the Company, the holders of the preferred stock are entitled to receive, prior to and in preference to the holders of the common shares, an amount equal to the Series A, Series A-1, or Series B Preferred Stock original issue price, plus declared and/or accrued but unpaid dividends. In the event of any such liquidation event, after the payment of all preferential amounts required to be paid to the holders of shares of preferred stock, the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of the shares of preferred stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted into Common Stock pursuant to the terms of the Certificate of Incorporation immediately prior to such liquidation event.

9. Warrants

The Company issued warrants to purchase 6,745 shares of common stock in 2018 in conjunction with convertible debt financing that have a redemption provision providing the holder the right to have the Company redeem all or any portion of the warrant (or shares it has converted into) at a purchase price equal to the fair market value of the shares as determined by the board of directors or an independent appraiser. As a result of this redemption provision, the warrants have been classified as a liability in the financial statements based on ASC 480 – Distinguishing Liabilities from Equity. These warrants have an exercise price of \$0.48 per share and a term of 10 years. The warrants are marked to market each reporting period. The fair value is \$60,933 and \$70,283 at September 30, 2023 and December 31, 2022, respectively.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The Company also issued warrants in 2016 and 2019 which did not meet the criteria under ASC 480 to be classified as a liability, and instead meet equity classification criteria. The 11,466 warrants issued in 2016 expired upon the initial public offering in June 2023.

The following table summarizes information about warrants outstanding at September 30, 2023:

Year Granted	Exercise Price	Warrants Outstanding			Warrant Exercisable		
		Number of Warrants at 9/30/2023	Weight Average Remaining Contractual Life	Weight Average Exercise Price	Number of Warrants at 9/30/2023	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price
2018	\$ 0.48	47,890	4.5 years	\$ 0.48	47,890	4.5 years	\$ 0.48
2019	\$ 5.28	215,846	2.4 years	\$ 5.28	215,846	2.4 years	\$ 5.28
2023	\$ 6.25	60,000	4.7 years	\$ 6.25	60,000	4.7 years	\$ 6.25
		<u>323,736</u>		<u>\$ 4.75</u>	<u>323,736</u>		<u>\$ 4.75</u>

10. Stock Options

In March 2023, the Company's Board of Directors and stockholders approved the 2023 Stock Incentive Plan ("2023 Plan"). The 2023 Plan allows the Committee to grant up to 2,000,000 shares of Common Stock in the form of incentive and non-statutory stock options, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, and non-employees. As of September 30, 2023, options to purchase 40,000 shares of common stock had been granted and were outstanding under the 2023 Plan and 1,960,000 shares of common stock were available for grant under the plan.

During 2016, the Company established the Azitra Inc. 2016 Stock Incentive Plan (the Plan) which provides for the granting of stock options and restricted shares to the Company's employees, officers, directors, advisors and consultants. As of September 30, 2023, options to purchase 1,248,255 shares of common stock had been granted and were outstanding under the 2016 Plan and 242,345 shares of common stock were available for grant under the plan.

During the three and nine months ended September 30, 2023 the Company granted stock options to purchase 40,000 shares of common stock and during the three and nine months ended September 30, 2022 the Company did not grant any stock options under this plan. During the three and nine months ended September 30, 2023, the Company recognized stock compensation expense of \$39,073 and \$116,661, respectively, relating to the issuance of service-based stock options. During the three and nine months ended September 30, 2022, the Company recognized stock compensation expense of \$44,329 and \$155,138, respectively, relating to the issuance of service-based stock options. At September 30, 2023, there was \$361,288 of unamortized compensation expense that will be amortized over the remaining vesting period. At September 30, 2023 and 2022, there were 13,120 performance-based options outstanding with a fair value of \$109,551. During the three and nine months ended September 30, 2023 and 2022, the Company did not recognize any compensation expense for performance-based options. The Company determined the options qualified as plain vanilla under the provisions of SAB 107 and the simplified method was used to estimate the expected option life.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following table summarizes information about options outstanding and exercisable at September 30, 2023:

Exercise Price	Options Outstanding			Options Exercisable		
	Number of Options at 9/30/2023	Weight Average Remaining Contractual Life	Weight Average Exercise Price	Number of Options at 9/30/2023	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price
\$ 0.48	246,137	2.3 years	\$ 0.48	246,137	2.3 years	\$ 0.48
\$ 0.93	202,040	2.3 years	\$ 0.93	201,593	2.3 year	\$ 0.93
\$ 1.70	800,078	7.5 years	\$ 1.70	547,151	7.3 years	\$ 1.70
\$ 2.07	40,000	9.9 years	\$ 2.07	1,667	9.9 years	\$ 2.07
	<u>1,288,255</u>			<u>996,548</u>		

Total stock option activity for the nine months ended September 30, 2023, is summarized as follows:

	Shares	Weighted Average Exercise Price
Outstanding at December 31, 2022	1,290,325	\$ 1.27
Granted	40,000	2.07
Exercised	—	—
Forfeited	(42,070)	0.87
Outstanding at September 30, 2023	<u>1,288,255</u>	<u>\$ 1.31</u>

There are 242,345 shares available for future grant under the 2016 Plan and 1,960,000 available under the 2023 Plan at September 30, 2023.

11. Fair Value Measurements

The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of:

September 30, 2023

Description	Level 1	Level 2	Level 3	Total
Liabilities				
Common stock warrants	\$ —	\$ —	\$ 60,933	\$ 60,933
Total	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 60,933</u>	<u>\$ 60,933</u>

December 31, 2022

Description	Level 1	Level 2	Level 3	Total
Liabilities				
Common stock warrants	\$ —	\$ —	\$ 70,283	\$ 70,283
2022 Convertible Notes	\$ —	\$ —	\$ 5,600,000	\$ 5,600,000
Total	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 5,670,283</u>	<u>\$ 5,670,283</u>

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following table presents the changes in Level 3 instruments measured on a recurring basis for the period ended September 30, 2023:

Balance at December 31, 2022	\$	5,670,283
Changes in fair value of warrants		(5,621)
Changes in fair value of 2022 Convertible Notes		800,000
Balance at March 31, 2023	\$	6,464,662
Changes in fair value of warrants		94,036
Changes in fair value of 2022 Convertible Notes		2,830,100
Conversion of 2022 Convertible Notes		(9,230,100)
Balance at June 30, 2023	\$	158,698
Changes in fair value of warrants		(97,765)
Balance at September 30, 2023	\$	60,933

At September 30, 2023 and December 31, 2022, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the following assumptions:

	September 30, 2023	December 31, 2022
Underlying common stock value	\$ 1.50	\$ 12.09
Expected term (years)	4.54	5
Expected volatility	93%	86%
Risk free interest rate	3%	3%
Dividend yield	—%	—%

Fluctuation in the fair value of the Company's Common stock is the primary driver for the change in the Common Stock Warrant liability valuation during each year. As the fair value of the Common stock increases the value to the holder of the instrument generally increases.

Prior to their redemption, fluctuations in the various inputs, including the enterprise value, time to liquidity, volatility, and discount rate are the primary drivers for the changes in valuation of the 2022 Convertible Notes each reporting period. As the fair value of the enterprise value, estimated time to liquidity, volatility, and discount rate increase, the value to the holder of the 2022 Convertible Notes generally increases.

12. Net Loss Per Share

Basic and diluted net loss per share were calculated as follows:

The numerator for basic and diluted net loss per share is as follows for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended		Nine Months Ended	
	2023	2022	2023	2022
Net loss	\$ (1,943,289)	\$ (2,417,620)	\$ (8,829,996)	\$ (6,633,790)
Dividends on preferred stock	—	(692,246)	(1,355,347)	(2,076,737)
Net loss attributable to common stockholders	\$ (1,943,289)	\$ (3,109,866)	\$ (10,185,343)	\$ (8,710,527)

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The denominator is as follows for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended		Nine Months Ended	
	2023	2022	2023	2022
Weighted average common stock outstanding, basic and diluted	12,097,643	1,043,988	5,173,925	1,043,913
\$0.01 warrants	—	11,467	7,182	11,467
Total	12,097,643	1,055,455	5,181,107	1,055,380

Net loss per share, basic and diluted is as follows for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended		Nine Months Ended	
	2023	2022	2023	2022
Net Loss per share, basic and diluted	\$ (0.16)	\$ (2.95)	\$ (1.97)	\$ (8.25)

The following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:

	September 30,	
	2023	2022
Options to purchase shares of common stock	1,288,255	1,290,318
Warrants outstanding	323,736	11,467
Total	1,611,991	1,301,785

13. Commitments and Contingencies

Legal

The Company is subject to legal proceedings or claims which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

License Agreement

Effective January 26, 2022, the Company entered into an Exclusive License Agreement (the License Agreement) with an unrelated third party. Under the License Agreement, the Company is granted an exclusive license for certain patents and a non-exclusive license for certain know-how. The License Agreement continues until the later of the expiration of the last to expire licensed patent or ten years after the first commercial sale of the first licensed therapeutic or non-therapeutic product. The Company may terminate the License Agreement at any time by providing at least 30 days written notice to the third party. The License Agreement is also terminated upon breach of a material obligation under the agreement or bankruptcy. Upon any termination of the License Agreement, neither party is relieved of obligations incurred prior to the termination.

During the three and nine months ended September 30, 2023 and 2022, the Company capitalized payments made under this license agreement in the amount of \$0 and \$15,263, respectively. During the three months ended September 30, 2023, the Company expensed the remainder of the capitalized balance.

Operating Leases

The Company leases office and lab space in Branford, CT; Groton, CT; and Laval, Quebec. The Company's leases expire at various dates through May 31, 2027. Most leases are for a fixed term and for a fixed amount. The Company is not a party to any leases that have step rent provisions, escalation clauses, capital improvement funding or payment increases based on any index or rate.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

During 2020, the Company entered into a new lease agreement for the Company's primary office and laboratory space in Branford, CT. The Branford lease requires monthly payments of \$13,033 for the first year of the lease, which increases approximately 2% in each of the following years. The Branford lease also requires the Company to pay a pro-rata share of common area maintenance.

During May 2021, the Company entered into a new lease for office and laboratory space in Groton, CT. The Groton lease required monthly payments of \$4,234, which was increased to \$6,824 in September 2021 upon leasing additional space. The Groton lease is initially for a one-year term, with up to three additional years renewal available.

Future minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next five years follow:

	2023	\$	81,354
	2024		337,708
	2025		278,928
	2026		205,877
	2027		73,725
	Thereafter		—
	Total future undiscounted lease payments		<u>977,592</u>
		Less interest	<u>(62,597)</u>
		Present value of minimum lease payments	<u>\$ 914,995</u>

Rent expense for all operating leases was \$84,714 and \$254,142 for the three and nine months ended September 30, 2023. The weighted average lease term for all operating leases is 3.2 years. The weighted average discount rate for all operating leases is 4.25%.

Finance Leases

During 2023, the Company entered into an agreement with Hewlett Packard to lease equipment. The lease requires monthly payments of \$1,478, including tax. The lease is for a 3-year term with option of purchase or extension at term end. The remaining lease term is 2.8 years and the discount rate is 9.60%.

The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of September 30, 2023. value of the minimum payments as of September 30, 2023.

	2023	4,435
	2024	\$ 17,740
	2025	17,740
	2026	10,349
	Thereafter	—
	Total future undiscounted lease payments	<u>50,264</u>
		Less interest
		<u>(6,058)</u>
		Present value of minimum lease payments
		<u>\$ 44,206</u>

Lease expense for the finance lease was \$2,580 for the three and nine months ended September 30, 2023. Interest expense for the finance lease was \$710 for the three and nine months ended September 30, 2023.

AZITRA, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

14. Retirement Plan

Effective January 1, 2019, the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate, an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1, 2020, the Plan was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed. Total employer matching contributions were \$2,809 and \$7,634 for the three and nine months ended September 30, 2023, respectively. Total employer matching contributions were \$3,926 and \$18,945 for the three and nine months ended September 30, 2022, respectively.

15. Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist principally of cash and accounts receivable.

For the three and nine months ended September 30, 2023 and 2022, all service revenue was from one customer. For the three and nine months ended September 30, 2023, there was no grant revenue and for the three and nine months ended September 30, 2022, all grant revenue was from one grantor.

The cash balance identified in the balance sheet is held in an account with a financial institution and insured by the Federal Deposit Insurance Corporation (FDIC) up to \$250,000. At times, cash maintained on deposit may be in excess of FDIC limits.

16. Related Parties

Total related party revenue was \$310,700 and \$596,000 for the three and nine months ended September 30, 2023. Total related party revenue was \$48,500 and \$253,500 for the three and nine months ended September 30, 2022. Accounts receivable due from the related party was \$0 and \$175,000 at September 30, 2023 and December 31, 2022, respectively. Contract liabilities from the related party was \$0 and \$156,000 at September 30, 2023 and December 31, 2022, respectively.

In September 2022 the Company entered into a convertible promissory note totaling \$4,350,000 of which \$4,000,000 was attributable to an entity who was also an investor in the Company's Series A, A-1, and B Preferred Stock financing (See Note 7). This entity received 1,697,490 shares of common stock upon conversion of the promissory notes for principal and interest of \$4,243,726.

17. Subsequent Events

The Company has evaluated events subsequent to the balance sheet date through November 14, 2023, the date these condensed financial statements are issued.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statement

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto contained elsewhere in this report. The information contained in this quarterly report on Form 10-Q is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this report and in our other filings with the Securities and Exchange Commission, or SEC, including our Prospectus dated June 15, 2023 and filed with the SEC on June 21, 2023.

In this report we make, and from time to time we otherwise make written and oral statements regarding our business and prospects, such as projections of future performance, statements of management’s plans and objectives, forecasts of market trends, and other matters that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements containing the words or phrases “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimates,” “projects,” “believes,” “expects,” “anticipates,” “intends,” “target,” “goal,” “plans,” “objective,” “should” or similar expressions identify forward-looking statements, which may appear in our documents, reports, filings with the SEC, and news releases, and in written or oral presentations made by officers or other representatives to analysts, stockholders, investors, news organizations and others, and in discussions with management and other of our representatives.

Our future results, including results related to forward-looking statements, involve a number of risks and uncertainties, including those risks included in the “Risk Factors” section in our Prospectus dated June 15, 2023 and filed with the SEC on June 21, 2023. No assurance can be given that the results reflected in any forward-looking statements will be achieved. Any forward-looking statement speaks only as of the date on which such statement is made. Our forward-looking statements are based upon assumptions that are sometimes based upon estimates, data, communications and other information from suppliers, government agencies and other sources that may be subject to revision. Except as required by law, we do not undertake any obligation to update or keep current either (i) any forward-looking statement to reflect events or circumstances arising after the date of such statement or (ii) the important factors that could cause our future results to differ materially from historical results or trends, results anticipated or planned by us, or which are reflected from time to time in any forward-looking statement.

General

We were formed in January 2014 as a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products. We are an early-stage clinical biopharmaceutical company and have not commenced commercial operations.

To date, we have capitalized our operations primarily through a series of private placements of our convertible preferred stock and convertible promissory notes and our initial public offering, IPO, of common stock which closed on June 21, 2023. In connection with our IPO, we issued 1.5 million shares of our common stock at a public offering price of \$5 per share. Concurrent with the close of our IPO, all of our outstanding shares of convertible preferred stock and convertible promissory notes converted into a total of 8,951,526 shares of our common stock. As of November 14, 2023, we had 12,097,643 shares of our common stock issued and outstanding. Except as otherwise indicated, all share and share price this report gives effect to a forward stock split effected on May 17, 2023 at a ratio of 7.1-for-1.


Overview

We focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. Our initial focus is on the development of genetically engineered strains of *Staphylococcus epidermidis*, or *S. epidermidis*, which we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies. The particular species demonstrates a number of well-described properties in the skin. As of the date of this report, we have identified among our microbial library over 60 distinct bacterial species that we believe are capable of being engineered to create living organisms or engineered proteins with significant therapeutic effect.

We are a pioneer in genetically engineered bacteria for therapeutic use in dermatology. Our goal is to leverage our platforms and internal microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or peptides to treat skin diseases. Our initial focus is on the development of our current product candidates, including:

- **ATR-12**, a genetically modified strain of *S. epidermidis* for treating the orphan disease, Netherton syndrome, a chronic and sometimes fatal disease of the skin estimated to affect approximately one in every 100,000, but its prevalence may be underestimated due to misdiagnosis caused by similarities to other skin diseases. We received Pediatric Rare Disease Designation for ATR-12 by the United States Food and Drug Administration, or FDA, in 2019. In December 2022, we submitted an investigational new drug application, or IND, for a Phase 1b clinical trial of ATR-12 in Netherton syndrome patients, and on January 27, 2023 we received notification from the FDA that the “study may proceed” with respect to the proposed Phase 1b clinical trial. We expect to commence our Phase 1b clinical trial in December of 2023 and report initial results in mid-2024.
- **ATR-04**, a genetically modified strain of *S. epidermidis* for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor, or EGFRi, targeted therapy. We intend to submit an IND for a Phase 1b clinical trial in certain cancer patients undergoing EGFRi targeted therapy by the first half of 2024. Subject to FDA clearance of our IND, we expect to commence our Phase 1b clinical trial in the second half of 2024.
- **ATR-01**, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), scaly skin disease with an estimated incidence and prevalence of 1 in 250, which suggests a total patient population of 1.3 million in the United States. We are planning to complete lead optimization and IND-enabling studies in 2023 and 2024 to support an IND filing target in late 2024 or early 2025.
- Two separate strains of bacterial microbes being investigated and developed by us and Bayer Consumer Care AG, the consumer products division of Bayer AG, or Bayer, the international life science company. We entered into a Joint Development Agreement, or JDA, with Bayer in December 2019. Under the terms of the JDA, we are responsible for testing our library of bacterial strains and their natural products for key preclinical properties. After screening through hundreds of strains, we and Bayer have selected two particular strains to move forward into further development. Bayer holds the exclusive option to license the patent rights to these strains. In December 2020, Bayer purchased \$8 million of our Series B preferred stock, which converted into 1,449,743 shares of our common stock, representing approximately 12.0%, of our outstanding common shares.

Azitra's pipeline



We also have established partnerships with teams from Carnegie Mellon University and the Fred Hutchinson Cancer Center, or Fred Hutch, two of the premier academic centers in the United States. Our collaboration with the Carnegie Mellon based team also takes advantage of the power of whole genome sequencing. This partnership is mining our proprietary library of bacterial strains for novel, drug like peptides and proteins. The artificial intelligence/machine learning technology developed by this team predicts the molecules made by microbes from their genetic sequences. The system then compares the predictions to the products actually made through tandem mass spectroscopy and/or nuclear magnetic resonance imaging to refine future predictions. The predictions can be compared to publicly available 2D and 3D protein databases to select drug like structures.

We hold an exclusive, worldwide license from Fred Hutch regarding the use of its patented SyngenicDNA Minicircle Plasmid, or SyMPL, technologies for all fields of genetic engineering, including to discover, develop and commercialize engineered microbial therapies and microbial-derived peptides and proteins for skin diseases. We are utilizing our licensed patent rights to build plasmids in order to make genetic transformations that have never been previously achieved. To date, our team has successfully engineered our lead therapeutic candidates without the SyMPL technology. However, we believe that SyMPL will open up the ability to make genetic transformations of an expanded universe of microbial species, and we expect that some or all of our future product candidates will incorporate the SyMPL technology. Our collaboration with Fred Hutch is led by Dr. Christopher Johnston, an expert in microbial engineering, and the innovator behind the SyMPL technology.

Our Strategy

Beyond our three lead product candidates and collaboration with Bayer, our goal is to develop a broad portfolio of product candidates focused on expanding the application of our platforms for precision dermatology. We believe that we have established a unique position in advancing the development of biologics for precision dermatology.

We intend to create a broad portfolio of product candidates for precision dermatology through our development of genetically engineered proteins selected from our proprietary microbial library of approximately 1,500 unique bacterial strains. Our strategy is as follows:

- **Build a sustainable precision dermatology company.** Our goal is to build a leading precision dermatology company with a sustainable pipeline of product candidates. To that end, we are focused on rapidly advancing our current pipeline of live biotherapeutic candidates while actively developing additional product candidates. Each of our current product candidates are proprietary and subject to pending patent applications. We expect that most, if not all, genetically engineered product candidates we develop will be eligible for patent protection.
- **Advance our lead product candidates, ATR-12 and ATR-04, through clinical trials.** In 2022, we obtained pre-IND correspondence with the FDA for purposes of discussing our proposed regulatory pathway for ATR-12 and obtaining guidance from the FDA on the preclinical plan leading to the filing and acceptance of an IND for ATR-12. In December 2022, we filed an IND for a first-in-human trial of ATR-12 in Netherton syndrome patients. On January 27, 2023, we received notification from the FDA that the “study may proceed” with respect to the proposed Phase 1b clinical trial, and we expect to commence our Phase 1b clinical trial in December of 2023, with initial results expected by mid-2024. We also plan to conduct a Phase 1b trial of our ATR-04 in certain cancer patients undergoing EGFRi therapy and expect to file an IND for ATR-04 by the first half of 2024.

- **Broaden our platform by selectively exploring strategic partnerships that maximize the potential of our precision dermatology programs.** We intend to maintain significant rights to all of our core technologies and product candidates. However, we will continue to evaluate partnering opportunities in which a strategic partner could help us to accelerate development of our technologies and product candidates, provide access to synergistic combinations, or provide expertise that could allow us to expand into the treatment of different types of skin diseases. We may also broaden the reach of our platform by selectively in-licensing technologies or product candidates. In addition, we will consider potentially out-licensing certain of our proprietary technologies for indications and industries that we are not ourselves pursuing. We believe our genetic engineering techniques and technologies have applicability outside of the field of medicine, including cosmetics and in the generation of clean fuels and bioremediation.
- **Leverage our academic partnerships.** We currently have partnerships with investigators at the Fred Hutchinson Cancer Center, Yale University, Jackson Laboratory for Genomic Medicine, and Carnegie Mellon University. We expect to leverage these partnerships and potentially expand them or form other academic partnerships to bolster our engineering platforms and expand our research and development pipeline.
- **Expand on our other potential product candidates.** Beyond our three lead product candidates, our goal is to develop a broad portfolio of product candidates focused on expanding the application of our platforms for precision dermatology. We have a proprietary platform for discovering and developing therapeutic products for precision dermatology. Our platform is built around a microbial library comprised of approximately 1,500 unique bacterial strains to allow screening for unique therapeutic characteristics and utilizes a microbial genetic technology that analyzes, predicts and engineers the proteins, peptides and molecules made by skin microbes. Our ability to genetically engineer intractable microbial species is uniquely leveraged by our exclusive license to the SyMPL technology.

Results of Operations

We are an early-stage clinical biopharmaceutical company, formed in January 2014, and have limited operating history. We have not commenced revenue-producing operations apart from limited service revenue derived through our JDA with Bayer. Under the terms of the JDA, we are responsible for testing our library of microbial strains and their natural products for key preclinical properties and Bayer reimburses us for our development costs. To date, our operations have consisted of the development of our proprietary microbial library, the identification, characterization and testing of certain bacterial species from our microbial library that we believe are capable of being engineered to provide significant therapeutic effect and the development of our initial product candidates.

Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022

The following table summarizes our results of operations with respect to the items set forth below for the three months ended September 30, 2023 and 2022, together with the percentage change for those items.

	Three Months Ended September 30,			
	2023	2022	\$ Change	% Change
Service revenue - related party	\$ 310,700	\$ 48,500	\$ 262,200	541%
Total revenue	310,700	48,500	262,200	541%
Operating expenses:				
General and administrative	1,755,908	1,054,570	701,338	67%
Research and development	548,524	1,364,380	(815,856)	(60)%
Total operating expenses	2,304,432	2,418,950	(114,518)	(5)%
Loss from operations	(1,993,732)	(2,370,450)	376,718	(16)%
Other income (expense):				
Interest income	634	3,201	(2,567)	(80)%
Interest expense	(710)	(31,333)	30,623	(98)%
Employee retention credit	—	—	—	—%
Forgiveness of accounts payable	—	—	—	—%
Change in fair value of convertible note	—	—	—	—%
Other expense	50,519	(19,038)	69,557	(365)%
Total other income (expense)	50,443	(47,170)	97,613	(207)%
Net loss	(1,943,289)	(2,417,620)	474,331	(20)%
Net loss	(1,943,289)	(2,417,620)	474,331	(20)%
Dividends on preferred stock	—	(692,246)	692,246	(100)%
Net loss attributable to common shareholders	\$ (1,943,289)	\$ (3,109,866)	\$ 1,166,577	(38)%

Service Revenue - Related Party

We generated \$310,700 of service revenue under the Bayer JDA during the third quarter of fiscal 2023 compared to service revenue of \$48,500 under the JDA for the comparable period in fiscal 2022. The increase of \$262,200 in service revenue is attributable to an increase in the amount of reimbursable development costs incurred in 2023.

General and Administrative

General and administrative costs during the third quarter of fiscal 2023 increased by \$701,338, or 67%, to \$1,755,908 from the prior year period. The increase was primarily related to an increase of \$856,000 in accounting, legal, financing, and insurance costs offset by a decrease of \$154,662 in payroll and related costs.

Research and Development

Research and development expenses include salaries and benefits of all research personnel, payments to contract research organizations, payments to research consultants, and the purchase of lab supplies. These expenses are offset by income earned from government grant payments. We generate grant revenue on contracts with various federal agencies and nonprofit research institutions for general research conducted by us. These grant arrangements also do not meet the criteria for revenue recognition and amounts earned under these grant contracts are recorded as a negative research and development expense.

During the third quarter of fiscal 2023, research and development expenses decreased by \$815,856, or 60%, to \$548,524 from the prior year period. The decrease was primarily related to a decrease of \$735,000 in research and development related costs attributable to our efforts in moving our Netherton program forward and a net decrease in payroll and related costs of \$293,000 attributable to a reduction in staff offset by a net increase in CMC costs of \$212,144 attributable to our efforts in moving our Netherton program forward. There was no government and nonprofit grant revenue received by us during the second quarter of fiscal 2023 or 2022.

We expect our research and development expenses to significantly increase in the future due primarily to our planned clinical trial activity and continued development of product candidates.

Other Income (Expense)

Our other income (expense) consists of refundable research and development credits, valuation of warrants, loss on disposal of equipment, loss on foreign currency and interest expense. During the third quarter of fiscal 2023, other income (expense) increased by \$97,613, or 207%, compared to the comparable period in fiscal 2022. The increase was primarily related to an increase of \$97,676 attributable to the valuation of the warrants, an increase of \$29,365 attributable to interest expense, an decrease of \$41,417 attributable to a loss on disposal of equipment and by a net increase of \$11,989 attributable to other income and expense.

Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022

The following table summarizes our results of operations with respect to the items set forth below for the for the nine months ended September 30, 2023 and 2022 together with the percentage change for those items.

	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Service revenue - related party				
Total revenue	\$ 596,000	\$ 253,500	\$ 342,500	135%
	596,000	253,500	342,500	135%
Operating expenses:				
General and administrative	3,443,559	2,583,818	859,741	33%
Research and development	2,188,795	4,425,195	(2,236,400)	(51)%
Total operating expenses	5,632,354	7,009,013	(1,376,659)	(20)%
	—	—	—	—%
Loss from operations	(5,036,354)	(6,755,513)	1,719,159	(25)%
	—	—	—	—%
Other income (expense):				
Interest income	1,184	4,056	(2,872)	(71)%
Interest expense	(166,729)	(66,781)	(99,948)	150%
Employee retention credit	—	229,813	(229,813)	(100)%
Forgiveness of accounts payable	56,285	—	56,285	100%
Change in fair value of convertible note	(3,630,100)	—	(3,630,100)	100%
Other expense	(54,282)	(45,365)	(8,917)	20%
Total other income (expense)	(3,793,642)	121,723	(3,915,365)	(3,217)%
	—	—	—	—%
Net loss	(8,829,996)	(6,633,790)	(2,196,206)	33%
	—	—	—	—%
Net loss	(8,829,996)	(6,633,790)	(2,196,206)	33%
Dividends on preferred stock	(1,355,347)	(2,076,737)	721,390	(35)%
Net loss attributable to common shareholders	\$ (10,185,343)	\$ (8,710,527)	\$ (1,474,816)	17%

Service Revenue - Related Party

We generated \$596,000 of service revenue under the Bayer JDA during the first nine months of fiscal 2023 compared to service revenue of \$253,500 under the JDA for the comparable period in fiscal 2022. The increase of \$342,500 in service revenue is attributable to an increase in the amount of reimbursable development costs in 2023.

General and Administrative

General and administrative costs during the first nine months of fiscal 2023 increased by \$859,741, or 33%, to \$3,443,559 from the prior year period. The increase was primarily related to an increase of \$1,167,000 in accounting, financing, legal and insurance costs offset by a decrease of \$381,000 in payroll and related costs and debt issuance costs, and a net increase of \$73,741 in other overhead expenses.

Research and Development

Research and development expenses include salaries and benefits of all research personnel, payments to contract research organizations, payments to research consultants, and the purchase of lab supplies. These expenses are offset by income earned from government grant payments. We generate grant revenue on contracts with various federal agencies and nonprofit research institutions for general research conducted by us. These grant arrangements also do not meet the criteria for revenue recognition and amounts earned under these grant contracts are recorded as a negative research and development expense.

During the first nine months of fiscal 2023, research and development expenses decreased by \$2,236,400, or 51%, to \$2,188,795 from the prior year period. The decrease was primarily related to a decrease of \$1,547,000 in research and development related costs attributable to our efforts in moving our Netherton program forward, a net decrease in payroll and related costs of \$702,000 attributable to a reduction in staff and a net decrease of \$12,600 of other costs. There was no government and nonprofit grant revenue received by us during the first nine months of fiscal 2023 or 2022.

We expect our research and development expenses to significantly increase in the future due primarily to our planned clinical trial activity and continued development of product candidates.

Other Income (Expense)

Our other income (expense) consists of refundable research and development credits, valuation of warrants, amortization of debt issuance costs, forgiveness of accounts payable, loss on disposal of equipment, loss on foreign currency translation, employee retention credit, change in fair value of the convertible note and interest expense. During the first nine months of fiscal 2023, other income (expense) increased by \$3,915,365, or 3,217%, compared to the comparable period in fiscal 2022. The increase was primarily related to an increase of \$3,630,100 attributable to the change in fair value of the convertible note, an increase of \$99,948 attributable to interest expense, an increase of \$229,813 attributable to the employee retention credit, a decrease of \$56,285 attributable to forgiveness of accounts payable and a net increase of \$11,789 attributable to other income and expense.

Financial Condition

As of September 30, 2023, we had total assets of approximately \$7.5 million and working capital of approximately \$3.4 million. As of September 30, 2023, our liquidity included approximately \$4.4 million of cash and cash equivalents. We believe that our cash on-hand will be sufficient to cover our proposed plan of operations into the first half of 2024 including dosing in the proposed Phase 1b clinical trial for ATR-12 and preclinical work on ATR-04. However, as of the date of this report, we believe that we will need additional capital in the first half of 2024, and there can be no assurance we will not need additional capital sooner. In addition, we believe that we will need additional capital to obtain marketing approval for ATR-12 and ATR-04, assuming such approval can be obtained at all. We intend to seek additional funds through various financing sources, including the sale of our equity and debt securities, licensing fees for our technology and joint ventures with industry partners. In addition, we will consider alternatives to our current business plan that may enable us to achieve revenue producing operations and meaningful commercial success with a smaller amount of capital. However, there can be no guarantees that such funds will be available on commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further pursue our business plan and we may be unable to continue operations.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, our common stockholders' ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Due to our accumulated deficit, recurring and negative cash flow from operations there is substantial doubt about our ability to continue as a going concern. Our financial statements include disclosure with respect to a substantial doubt about our ability to continue as a going concern and the report of our independent auditor includes an explanatory paragraph with respect to that substantial doubt.

Cash Flows

The following table shows a summary of our cash flows for the periods indicated:

	Nine Months Ended September 30,	
	2023	2022
Net cash used in operating activities	\$ (4,778,962)	\$ (6,176,777)
Net cash used in investing activities	\$ (258,274)	\$ (239,970)
Net cash provided by financing activities	\$ 5,944,907	\$ 4,310,807
Net increase (decrease) in cash	\$ 907,671	\$ (2,105,940)

Operating Activities

During the first nine months of fiscal 2023, operating activities used \$4.8 million of cash primarily driven by our net loss of \$8.8 million offset by non-cash items of \$4.0 million. During the comparable period of fiscal 2022, operating activities used \$6.2 million of cash primarily driven by our net loss of \$6.6 million offset by non-cash items of \$400,000.

Investing Activities

During the first nine months of fiscal 2023, investing activities used \$258,274 of cash primarily driven by \$235,000 thousand of trademark and patent costs and \$23,000 for the purchase of furniture and equipment. During the comparable period of fiscal 2022, investing activities used \$240,000 of cash primarily driven by \$221,000 of trademark and patent costs and \$19,000 for the purchase of furniture and equipment.

Financing Activities

During the first nine months of fiscal 2023, financing activities provided \$5.9 million in cash driven by proceeds from our initial public offering. During the comparable period of fiscal 2022, financing activities provided \$4.3 million in cash primarily driven by the proceeds from the convertible notes.

Critical Accounting Policies

During the nine months ended September 30, 2023, there were no material changes to our critical accounting policies previously disclosed in our Prospectus dated June 15, 2023 and filed with the SEC on June 21, 2023.

Critical Accounting Estimates

Our management's discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates. There were no material changes to our critical accounting estimates as reported in our Prospectus dated June 15, 2023 and filed with the SEC on June 21, 2023.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, pursuant to Rule 13a-15 of the Securities Exchange Act of 1934, as of September 30, 2023. In the course of that evaluation, we identified a material weakness as it relates to a lack of adequate segregation of accounting functions. We intend to increase staffing within our accounting infrastructure sufficient to facilitate proper segregation of accounting functions and to enable appropriate review of our internally prepared financial statements. Based upon the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of September 30, 2023.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1A. Risk Factors

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include our expectations, beliefs, intentions and strategies regarding the future. You should carefully consider the risk factors discussed in the “Risk Factors” section in our Prospectus dated June 15, 2023 and filed with the SEC on June 21, 2023. as, in light of those risks, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in our forward-looking statements. There have been no material changes in the risk factors included in our Prospectus dated June 15, 2023. The risk factors described in our Prospectus dated June 15, 2023 are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

Item 6. Exhibits.

Exhibit Number	Description	Method of Filing
3.1	Amended and Restated Certificate of Incorporation of the Registrant	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on June 21, 2023
3.2	Amended and Restated Bylaws of the Registrant	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on June 21, 2023
31.1	Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed electronically herewith
31.2	Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed electronically herewith
32.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).	Filed electronically herewith
101.INS	Inline XBRL Instance Document.	Filed electronically herewith
101.SCH	Inline XBRL Taxonomy Extension Schema Document.	Filed electronically herewith
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.	Filed electronically herewith
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.	Filed electronically herewith
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.	Filed electronically herewith
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.	Filed electronically herewith
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).	Filed electronically herewith

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AZITRA, INC.

Date: November 14, 2023

By: /s/ Francisco D. Salva
Francisco D. Salva,
President and Chief Executive Officer
(Principal Executive Officer)

Date: November 14, 2023

By: /s/ Norman Staskey
Norman Staskey
Chief Financial Officer
(Principal Financial Officer)

CERTIFICATIONS

I, Francisco D. Salva, certify that:

(1) I have reviewed this Form 10-Q of Azitra, Inc. (the "Company");

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

(4) The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; And

(5) The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

AZITRA, INC.

Date: November 14, 2023

By: /s/ Francisco D. Salva

Francisco D. Salva, Chief Executive Officer

CERTIFICATIONS

I, Norman Staskey, certify that:

- (1) I have reviewed this Form 10-Q of Azitra, Inc. (the "Company");
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
- (4) The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
 - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
 - (d) disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; And
- (5) The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

AZITRA, INC.

Date: November 14, 2023

By: /s/ Norman Staskey
Norman Staskey, Chief Financial Officer
(Principal Financial Officer)

**CERTIFICATION PURSUANT TO 18
U.S.C. 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Azitra, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Francisco D. Salva, the Chief Executive Officer, and Norman Staskey, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Francisco D. Salva
Francisco D. Salva,
Title: President and Chief Executive Officer

Dated: November 14, 2023

By: /s/ Norman Staskey
Norman Staskey,
Title: Chief Financial Officer

Dated: November 14, 2023

This certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.
